Pharmaceutical & Biotechnology
Medicenna Therapeutics
About this employer
Medicenna Therapeutics is a clinical-stage immunotherapy company in Toronto, ON, developing engineered interleukins for cancer and autoimmune and inflammatory diseases. Using its Superkine, BiSKIT and T-MASK platforms, it is advancing programs including MDNA11, an IL-2 super agonist in Phase 1/2 trials for solid tumours, and IL-2/IL-15 and IL-4/IL-13 pathway antagonists.